- Coordinator
- Istrazivacko Razvojni Centar Za Bioinzenjering Bioirc Doo, Serbia
- Runs
- 1 June 2023 to 31 May 2027
- Status
- Running
- EU funding
- €4.5m
- Total cost
- €4.5m
- Partners
- 19 organisations in 9 countries
- Type
- Research and Innovation Action
- Grant agreement
- 101080905
What the project is doing
In the project's own words, from its summary on CORDIS.
Heart failure (HF) is a pandemic currently affecting up to 15 million people in Europe. It is a complex clinical syndrome presenting with impaired heart function and is associated with poor quality of life for patients and high healthcare costs. There is a high clinical demand for novel artificial intelligence (AI) tools which will facilitate risk stratification, early diagnosis, and disease progression assessment in HF.
Such tools are essential to allow prompt initiation of evidence-based prevention and treatment strategies which will improve patient quality of life, reduce morbidity and mortality and the HF burden on healthcare. STRATIFYHF aims to develop, validate and implement the first AI-based, decision support system (DSS) for risk stratification, early diagnosis, and disease progression assessment in HF to accommodate both primary and secondary care clinical needs.
The DSS will integrate patient-specific demographic and clinical data using existing and novel technologies and establish AI-based tools for risk stratification and HF prediction using machine learning. Additionally, a mobile app will be developed to empower patients to better manage their condition, and health care professionals to make informed decision in selection of evidence-based HF prevention and treatment strategies.
Our multidisciplinary consortium, including three small-to-medium enterprises (SMEs) and two stakeholder organisations, will be guided by medical advice and regulatory and health technology experts to deliver the DSS as a medical class 2b device, reaching TRL 8 by the end of the project. STARTIFYHF will change the way in which HF is diagnosed today and thereby improve the quality and length of patients’ lives and lead to efficient and sustainable healthcare systems by reducing the number of HF-related hospital admissions and unnecessary referrals from primary to secondary care in Europe and beyond.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Istrazivacko Razvojni Centar Za Bioinzenjering Bioirc Doo | Kragujevac | Serbia | Coordinator |
| Pknm Solutions SARL | Colombier | Switzerland | Associatedpartner |
| Klinikum Der Universitaet Regensburg | Regensburg | Germany | Participant |
| Idryma Technologias Kai Erevnas | Irakleio | Greece | Participant |
| Bcn Health Economics & Outcomes Research SL | Barcelona | Spain | Participant |
| Servicio Madrileno De Salud | Madrid | Spain | Participant |
| Azienda Ospedaliero-Universitaria Careggi | Firenze | Italy | Third party |
| Azienda Unita' Sanitaria Locale Toscana Centro | Firenze | Italy | Third party |
| Universita Degli Studi Di Firenze | Florence | Italy | Participant |
| Gpcardio BV | Haarlem | Netherlands | Participant |
| Medcon International BV | Heemstede | Netherlands | Participant |
| Universitair Medisch Centrum Utrecht | Utrecht | Netherlands | Participant |
| Institut Za Kardiovaskularne Bolesti Vojvodine | Sremska Kamenica | Serbia | Third party |
| Udruzenje Za Srcanu Slabost Srbije | Belgrade | Serbia | Participant |
| University of Novi Sad, Faculty of Medicine Novi Sad | Novi Sad | Serbia | Participant |
| Univerza V Ljubljani | Ljubljana | Slovenia | Participant |
| Coventry University | Coventry | United Kingdom | Associatedpartner |
| The Chancellor Masters and Scholars of the University of Cambridge | Cambridge | United Kingdom | Associatedpartner |
| University of Newcastle Upon Tyne | Newcastle Upon Tyne | United Kingdom | Associatedpartner |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI